TRIMTECH Therapeutics enters strategic research collaboration with Biogen to advance small molecule degraders for neurodegenerative disease
TRIMTECH Therapeutics, a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, today announced it has entered into a strategic research collaboration, option, and license agreement with Biogen International GmbH.
16 Nov 11:36 · News-Medical